Results 11 to 20 of about 38,595 (290)

GLP-1RA Use and Thyroid Cancer Risk.

JAMA Otolaryngol Head Neck Surg
ImportanceThe increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RA) demands a better understanding of their association with thyroid cancer.ObjectiveTo estimate the risk of incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1RA vs other common glucose-lowering medications.Design, Setting, and ...
Brito JP, Herrin J, Swarna KS, Singh Ospina NM, Montori VM, Toro-Tobon D, Umpierrez GE, Galindo RJ, Deng Y, Mickelson MM, Shao H, Polley EC, McCoy RG.   +12 more
europepmc   +4 more sources

Cardiometabolic improvements, sleep apnea reduction, and biomarker modulation under dual GLP-1RA and SGLT2i therapy: a prospective study [PDF]

Pharmacia
This prospective cohort study explored the cardiometabolic, sleep-related, and biomarker effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium–glucose cotransporter-2 inhibitors (SGLT2i), and their combination in patients with heart ...
Petar Kalaydzhiev, Tsvetelina Velikova, Gergana Voynova, Radostina Ilieva, Natalia Spasova, Slavi Yakov, Elena Kinova, Georgi H. Vasilev, Radosveta Wells, Assen Goudev   +9 more
doaj   +4 more sources

GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects. [PDF]

J Clin Invest
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an essential drug class for treating type 2 diabetes, offering proven benefits in glycemic control, weight reduction, and cardiovascular and renal protection.
Cardoso P, Dennis JM, Pearson ER.
europepmc   +3 more sources

Decoding the hallmarks of GLP-1RA weight-loss super-responders. [PDF]

Biol Methods Protoc
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135,349 individuals treated with semaglutide and tirzepatide formulations and stratified them as “super responders” (>
Venkatakrishnan AJ, Murugadoss K, Soundararajan V.   +2 more
europepmc   +2 more sources

The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. [PDF]

J Eur Acad Dermatol Venereol
Abstract Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP‐1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction.
Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ.   +5 more
europepmc   +5 more sources

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD. [PDF]

Kidney Int Rep
Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of 2 clinical trials.
Singh AK, Anker SD, Pitt B, Rossing P, Ruilope LM, Ahlers C, Farag YMK, Lambelet M, Brinker MD, Rohwedder K, Filippatos G, FIDELIO-DKD and FIGARO-DKD Investigators.   +11 more
europepmc   +4 more sources

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Frontiers in Endocrinology, 2022
Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI ...
Shichao Dong, Chuan Sun
doaj   +1 more source

GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease

, 2022
Objectives: We assessed the effect of GLP-1RAs on ischemic stroke prevention in the Asian population with type 2 diabetes (T2D) without established cardiovascular disease.
Chia-Hung Kao (173343), Chien-Ning Huang (1739806), Chung Y. Hsu (7255547), Hsin-Hung Chen (789932), Kai-Chieh Hu (10512205), Yi-Sun Yang (1739800)   +5 more
core   +1 more source

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis

European Psychiatry, 2023
Background Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs).
Congqin Chen, Rijing Zhou, Fang Fu, Jie Xiao   +3 more
doaj   +1 more source

Semaglutide seems to be more effective the other GLP-1Ras [PDF]

Annals of Translational Medicine, 2017
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced as treatment options for type 2 diabetes (T2DM) in 2005 (1). They have become popular because of their efficacy and durability in relation to glycaemic control, and their low risk of hypoglycaemia in combination with weight loss in most patients (2,3).
Holst, Jens Juul, Madsbad, Sten
openaire   +3 more sources